CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

prednisoloneWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D012135 Respiratory Sounds NIH 0.71

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0010307 Stridor HPO 0.71

There is one clinical trial.

Clinical Trials

1 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children

We can not predict which wheezing child younger than 3 years of age benefits from systemic glucocorticoid and which one does not. It is not known whether the differences in the efficacy are related to the differences in viral etiology, atopy, immunogical maturity or age of the patient. The study aims to answer the following questions: 1. What is the viral etiology of acute childhood expiratory wheezing? 2. What is the efficacy of prednisolone in relation to age, atopy and viral etiology in acute childhood wheezing? 3. Does prednisolone treatment increase risk for secundary bacterial infection in acute childhood expiratory wheezing? 4. What is the significance of inflammatory markers in predicting the efficacy of systemic steroid or patient outcome in acute childhood expiratory wheezing? Study will follow randomized, double blind, placebo-controlled parallel design. Study will start in Septemper 2000 and will be performed at the Department of Pediatrics, Turku University Hospital, Turku Finland. The study population will be 300 hospitalized wheezing children aged 3 months – 15 years. Investigational drug will be prednisolone, first dose 2 mg/kg, then 2 mg/kg/d/3 (max. 60 mg/vrk) p.o. for 3 d and comparative drug will be placebo tablet similar to investigational drug with the equal dosage. The primary outcome will be the time until ready for discharge. The study will provide new and important information for the diagnostics, treatment, disease outcome and prevention of acute childhood expiratory wheezing.

NCT00494624 Wheezing Drug: prednisolone
MeSH:Respiratory Sounds
HPO:Crackles Rhonchi Stridor Wheezing

Primary Outcomes

Measure: The time until ready for discharge

Secondary Outcomes

Measure: Oxygen saturation during hospital stay

Measure: Wheeze and cough during two weeks after discharge from the hospital

Measure: Readmission to the out-patient clinic or hospital for recurrent wheezing during a two-month period after discharge

Measure: Blood eosinophil counts at discharge and two weeks later

Related HPO nodes (Using clinical trials)

HP:0030830: Crackles
Genes 20
SFTPA2 STN1 DSP CFTR CSF2RA PARN FAM13A RTEL1 TERT SCNN1A SFTPC CSF2RB SFTPA1 MUC5B DPP9 SCNN1G ATP11A ABCA3 SCNN1B TERC
Protein Mutations 0
SNP 0
HP:0030831: Rhonchi
Protein Mutations 0
SNP 0
HP:0010307: Stridor
Genes 32
AGRN COQ2 SLC18A3 IGHMBP2 SCN4A SYT2 TSPYL1 SLC18A2 SCN4A SLC25A1 SLC5A7 FLNA SNAP25 SLC18A2 CHAT SLC25A1 MAP3K7 SERPING1 D2HGDH PLP1 PAX8 TRPV4 SCN4A TRPV4 COQ2 SLC5A7 SLC52A3 COL13A1 SLC52A3 SCARF2 VAMP1 MYO9A
Protein Mutations 4
Q27E R16G R19C T164I
SNP 0
HP:0030828: Wheezing
Genes 5
CFTR DNAH1 SCNN1G SCNN1B SCNN1A
Protein Mutations 0
SNP 0